Table 5: Anti-inflammatory activity of Aceclofenac in niosomal and non-niosomal gel formulations.
Mean ± SD, n = 6
| Time (hr) | First group (control) HPMC (3%w/w) | Second group Aceclofenac gel of HPMC (3%w/w) | Third group Aceclofenac niosomal gel of HPMC (3%w/w) |
| % Swelling | % Inhibition | % Swelling | % Inhibition | % Swelling | % Inhibition |
| 0 | 76.6 ± 0.77 | __ | 76.6 ± 0.24 | __ | 76.6 ± 0.24 | __ |
| 0.5 | 85.2 ± 0.11 | __ | 55.4 ± 0.46 | 34.97 ± 0.89 | 54.11± 1.73 | 36.49 ± 3.54 |
| 1 | 85.3 ± 0.35 | __ | 45.4 ± 0.75 | 45.95 ± 8.6 | 46.21 ± 3.24 | 46.79 ± 4.82 |
| 2 | 85.46 ± 0.21 | __ | 40.65 ± 2.30 | 52.43 ± 6.42 | 34.77 ± 7.05 | 59.31 ± 9.52 |
| 3 | 85.61 ± 0.84 | __ | 37.2 ± 0.23 | 56.78 ± 5.98 | 21.65 ± 0.45 | 74.71 ± 10.45 |
| 4 | 85.72 ±1.13 | __ | 41.8 ± 0.4 | 51.32 ± 9.52 | 15.5 ± 10.08 | 81.91 ± 3.52 |
| 5 | 85.77 ± 0.23 | __ | 48.65 ± 1.45 | 43.28 ± 3.27 | 13.71 ± 0.29 | 84.02 ± 4.2 |
| 6 | 85.94 ± 0.63 | __ | 54.37 ± 1.98 | 37.16 ± 7.95 | 12.12 ± 0.18 | 85.89 ± 2.12 |